|
|
Article: Dynogen's GI, GU Products To Benefit From $50M Round.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical compounds.
Founded in March 2002, the company focuses on genitourinary (GU) and gastrointestinal (GI) disorders. It developed one of its products in-house, DDP200 for the treatment of overactive bladder, and in-licensed the other product, DDP225, to treat irritable bowel syndrome.
With the $50 million, Boston-based Dynogen plans to move DDP200 into a Phase IIa study in the first half of this year and to file an investigational new drug application with the FDA for ...